- Home
- ACIC vs PRAX Comparison
ACIC vs PRAX Comparison
Compare ACIC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- PRAX
- Stock Information
- Founded
- ACIC 1999
- PRAX 2015
- Country
- ACIC United States
- PRAX United States
- Employees
- ACIC N/A
- PRAX N/A
- Industry
- ACIC Property-Casualty Insurers
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- ACIC Finance
- PRAX Health Care
- Exchange
- ACIC Nasdaq
- PRAX Nasdaq
- Market Cap
- ACIC 556.0M
- PRAX 599.7M
- IPO Year
- ACIC N/A
- PRAX 2020
- Fundamental
- Price
- ACIC $10.80
- PRAX $38.55
- Analyst Decision
- ACIC Buy
- PRAX Strong Buy
- Analyst Count
- ACIC 1
- PRAX 10
- Target Price
- ACIC $16.00
- PRAX $116.50
- AVG Volume (30 Days)
- ACIC 219.6K
- PRAX 320.6K
- Earning Date
- ACIC 05-08-2025
- PRAX 05-02-2025
- Dividend Yield
- ACIC 4.63%
- PRAX N/A
- EPS Growth
- ACIC 3.21
- PRAX N/A
- EPS
- ACIC 1.49
- PRAX N/A
- Revenue
- ACIC $302,261,000.00
- PRAX $8,122,000.00
- Revenue This Year
- ACIC $5.58
- PRAX N/A
- Revenue Next Year
- ACIC $10.72
- PRAX N/A
- P/E Ratio
- ACIC $7.34
- PRAX N/A
- Revenue Growth
- ACIC 23.92
- PRAX 270.02
- 52 Week Low
- ACIC $8.82
- PRAX $26.70
- 52 Week High
- ACIC $15.08
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- ACIC 41.77
- PRAX 53.72
- Support Level
- ACIC $10.68
- PRAX $35.21
- Resistance Level
- ACIC $10.94
- PRAX $38.90
- Average True Range (ATR)
- ACIC 0.30
- PRAX 2.09
- MACD
- ACIC -0.03
- PRAX 0.07
- Stochastic Oscillator
- ACIC 28.40
- PRAX 69.58
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.